Journal
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
Volume 7, Issue -, Pages 74-82Publisher
CELL PRESS
DOI: 10.1016/j.omtm.2017.09.003
Keywords
-
Categories
Funding
- Bill and Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery [OPP1040731]
- Defense Advanced Research Projects Agency [W31PQ4-14-1-0010]
- Army Research Office [W911NF-14-C-0001]
- Bill and Melinda Gates Foundation [OPP1040731] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
Monoclonal antibodies (mAbs) have wide clinical utility, but global access is limited by high costs and impracticalities associated with repeated passive administration. Here, we describe an optimized electroporation-based DNA gene transfer platform technology that can be utilized for production of functional mAbs in vivo, with the potential to reduce costs and administration burdens. We demonstrate that multiple mAbs can be simultaneously expressed at protective concentrations for a protracted period of time using DNA doses and electroporation conditions that are feasible clinically. The expressed mAbs could also protect mice against lethal influenza or Ebola virus challenges. Our findings suggest that this DNA gene transfer platform technology could be a game-changing advance that expands access to effective mAb therapeutics globally.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available